The recent case report by Thompson and colleagues on late-onset neutropenia with clozapine raises a few questions (1) . The authors do not define mild neutropenia and incorrectly call an absolute neutrophil count (ANC) of 1.86 x 109/L mild neutropenia. The most accepted definition of mild neutropenia is an ANC of 1.0 to 1.5 x 109/L (2). Further, the authors do not elaborate on the role of valproic acid in the presentation of clozapine-induced neutropenia. Valproic acid is independently associated with neutropenia (3) . In addition, a case report describes a patient on a combination of sodium valproate and clozapine who developed a potentially serious drop in white cell and neutrophil counts that reversed on discontinuation of valproate (4) . On the basis of this report, the investigators recommended that consideration should be given to stopping sodium valproate before the thresholds are reached for the discontinuation of clozapine. Clozapine-induced neutropenia is much more common than agranulocytosis (cumulative incidence of 2.7% and 0.73%, respectively) (5), which means that a substantial proportion of patients experiencing neutropenia with clozapine treatment do not progress to agranulocytosis. Transient or benign neutropenia not progressing to agranulocytosis has been described in the literature, and some patients with mild neutropenia have been shown to do well on continued treatment with clozapine (6) . It has been suggested that drug interaction may be responsible for neutropenia in clozapine-treated patients and that clozapine need not necessarily be discontinued (7) . Given that clozapine is administered to treatment-resistant patients, balancing potential side effects like agranulocytosis and clinical deterioration assumes greater significance, especially in patients developing mild neutropenia while taking other medications with a potential to cause neutropenia. Thus it would have been interesting to see whether this patient's neutropenia would have resolved had the valproic acid been discontinued. Nevertheless, this report highlights the need for future research to explore alternate options when treating clozapine-induced mild neutropenia while continuing clozapine and also to devise means to differentiate benign neutropenia from neutropenia progressing to agranulocytosis.
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Dear Editor:
We appreciate the opportunity to respond to Dr Duggal and Dr Singh, and we welcome their comments. We agree with their observation that an accepted strict definition of mild neutropenia is an absolute neutrophil count of 1.0 to 1.5 x 109/L. We used the term mild neutropenia to reflect the neutrophil count being designated within the "amber" range as defined by the Clozaril Patient Management System (1). This designation prompts the need for biweekly blood draws.
We are aware that the role of concomitant valproic acid needs to be considered, given the evidence that it can cause direct bone marrow suppression producing blood dyscrasias including neutropenia (2) .
In this case, there was no evidence of neutropenia with valproic acid prior to the institution of clozapine. Further, cessation of the clozapine alone resulted in a gradual resolution of the neutropenia, which was sustained, to our knowledge, for at least 2 years and despite the addition of risperidone and the patient's remaining on valproic acid.
With hindsight, it might have been worthwhile to discontinue the valproic acid prior to being forced to cease the clozapine. However, the history of a grand mal seizure would argue against ceasing the valproic acid in the first instance.
Thankfully, in this particular scenario, the patient's symptoms responded satisfactorily to risperidone, with the added benefit of less onerous hematological surveillance.
It is an important issue to consider when a patient has failed trials with other atypical medication, necessitating administration of clozapine. In such a situation, premature cessation of clozapine may result in clinical deterioration.
We would then agree that a judicious trial off valproic acid in the first instance would be warranted.
The issue of the role of drug interaction in producing the late-onset neutropenia is interesting, pertinent, and needs further delineation. We accept the suggestion that a complex interaction between valproic acid and clozapine, and perhaps some other clinically undetected factor, lowered the threshold for a clozapine-induced neutropenia that might not have progressed to agranulocytosis. Certainly, Gerson has suggested that the mechanism of toxicity in most patients with neutropenia who do not progress to agranulocytosis is distinct from that responsible for agranulocytosis (3).
The case report cited by Dr Duggal and Dr Singh appears to exemplify this situation (4): reversible neutropenia was temporally related to the addition of other medication in a patient taking both clozapine and valproic acid.
We believe that our report and the valuable comments of Dr Duggal and Dr Singh should prompt further investigation into the etiology of mild neutropenia in the context of clozapine use. We encourage future researchers who have the access and opportunity to explore carefully the burgeoning databases on clozapine patients-in particular, to tease out factors associated with this clinically relevant phenomenon with respect to the role of drug interaction and to delineate factors that may determine the outcome of the neutropenia.
There have been several studies regarding methylphenidate abuse in university settings, especially in the US; however, very little about statistics regarding intranasal and intravenous use are present in the literature. The statistics about intranasal and intravenous use are highly important in light of the dramatic rise in methylphenidate abuse in the last 15 years.
Several studies have shown that there are similarities between cocaine and methylphenidate in their ability to block dopamine transporters, especially when taken intravenously. Some researchers postulated that the shorter effects of cocaine might account for its potential to be heavily abused (2).
A similar study done at the University of Michigan by Teter and others (3) , in which a sample of 2250 students was studied, appears consistent with Volkow and others. The interesting finding, though, was that 79% of those who abuse methylphenidate started taking it during college, while 19% started in high school. Methylphenidate users accounted for only 2% of the students studied.
Other US college surveys have shown much higher prevalence. A survey at the University of Pennsylvania showed that almost 9% of undergraduates used someone else=s prescription medications, most of which were methylphenidates. Another survey showed that 16% of students at a small liberal arts college reported having tried methylphenidate recreationally and that 12.7% reported having taken it intranasally. A more recent survey in 2002 involving students at the University of Florida showed that 1.5% used ritalin recreationally in the 30 days prior to the study (4).
Barrett and others mentioned that prescription diversion was the primary source of methylphenidate use in this sample; however, other sources are prevalent. Methylphenidate is one of the 10 most frequently stolen controlled medications, although this may not necessarily be the case regarding college students. The popularity of the drug among college students could also be attributed to the competitive nature of colleges. The drug has been linked with some students' desire to excel in a competitive academic environment, because it helps them to stay focused through periods of fatigue.
Several studies have reported how best to curb methylphenidate abuse. In addition to the suggestion put forth by Barrett and others, other researchers have suggested methods such as alternative pharmaceutical delivery systems that are not easily manipulated for injection or inhalation and the use of centralized prescription databases. We believe education would be one of the most effective ways to address this problem in a university setting, especially if, as suggested by Barrett and others, prescription diversion is a major source of access to methylphenidate. Education would be helpful in cases where only the person given the prescription, and not whoever eventually abuses the drug, is advised of the risks and benefits.
